
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded oral liquid containing neomycin sulfate, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing neomycin are listed in ointment, suspension, solution, tablet and cream forms.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Neomycin is an aminoglycoside antibiotic that a pharmacy may compound when a prescriber orders it.
Neomycin is an aminoglycoside antibiotic. It binds the 30S subunit of the bacterial ribosome and disrupts protein synthesis, killing bacteria, mainly gram-negative bacilli such as Escherichia coli and Klebsiella. Taken by mouth it is poorly absorbed, so it acts mostly inside the gut. Manufactured products include neomycin sulfate tablets and topical neomycin creams and ointments, alone or with a corticosteroid. The tablet label indicates it as adjunctive therapy to suppress normal bowel bacteria, such as before bowel surgery with erythromycin, and as adjunctive therapy in hepatic coma by reducing ammonia-forming gut bacteria. MedlinePlus describes topical neomycin for preventing or treating bacterial skin infections. A prescriber might order it compounded as an oral liquid, in a topical vehicle or combination that is not manufactured, or without a specific excipient. Compounded preparations are not FDA-approved and require a prescription.
Oral neomycin tablets carry a boxed warning: neomycin is absorbed after oral use and can cause kidney damage, permanent hearing loss and balance problems, and neuromuscular blockade with respiratory paralysis. Hearing loss can start after the drug is stopped, and the risk is higher with kidney impairment, older age, dehydration, longer use and certain inherited mitochondrial gene variants. Avoid combining it with other aminoglycosides, polymyxins, vancomycin, cisplatin, amphotericin B and potent diuretics such as furosemide. Do not take it with intestinal obstruction, inflammatory or ulcerative bowel disease, or a prior aminoglycoside allergy. It can reduce absorption of digoxin, penicillin V and vitamin B12 and can increase warfarin effect. Aminoglycosides can cause fetal harm. LactMed says oral or topical neomycin should leave very low levels in milk. Report hearing changes or reduced urination to your prescriber or pharmacist.
Neomycin is a bactericidal aminoglycoside that binds the 30S ribosomal subunit; it is active mainly against gram-negative bacilli and is not active against anaerobic bowel flora. About 97 percent of an oral dose is eliminated unchanged in feces; the small absorbed fraction is renally excreted, accumulates in renal cortex and inner ear with repeated dosing, and is released slowly over weeks. Protein binding is low. Neomycin sulfate tablets (Solaris Pharma) are indicated as adjunctive bowel flora suppression before surgery with erythromycin and as adjunctive therapy in hepatic coma; StatPearls notes neomycin is often reserved for patients unable to tolerate rifaximin and is second line to synthetic disaccharides such as lactulose. StatPearls describes use for constipation-predominant irritable bowel syndrome; this is not an FDA-approved indication. The label warns that neomycin is rapidly and almost totally absorbed from body surfaces other than the bladder after irrigation or topical use during surgery, with reports of deafness, renal failure and fatal neuromuscular blockade. Obtain serial audiometry, vestibular testing and renal function, especially in high-risk patients, and monitor digoxin levels and INR with warfarin. Prolonged therapy can cause malabsorption. Dosing is per prescriber. Neomycin is not a controlled substance.
Shake the bottle if your label says to. Measure each dose with the oral syringe or dosing cup the pharmacy gave you, never a kitchen spoon. Give the liquid slowly into the mouth. Rinse the syringe with water after each use. Call the pharmacy if you are unsure how to measure.
Storage depends on the vehicle. Water-based liquids with a preservative usually carry a USP <795> beyond-use date of up to 35 days; without a preservative they are kept refrigerated for up to 14 days. Oil-based (nonaqueous) oral liquids may carry up to 90 days. Your label states whether to refrigerate and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally